AnaptysBio Posts Diluted Earnings of $0.11 per Share as Third-Quarter Income Falls
Key Facts
AnaptysBio reported net income of $3.876 million for the three months ended September 30, 2026, and diluted earnings per share fell to $0.11 from $0.52 in the corresponding period of 2025, according to the company’s filing with the U.S. Securities and Exchange Commission. The year-over-year comparison puts the decline in profitability at the center of the quarterly report, as the company relied on royalty revenue from products partnered with GSK. The available evidence does not include documented analyst estimates, so the result cannot be described as missing a specific consensus figure. Revenue details present a more mixed picture than net income, with total collaboration revenue down as Jemperli royalties grew. The company also reported lower available liquidity and cash used by continuing operations during the quarter.
Collaboration revenue was $30.274 million in the quarter, compared with $76.320 million in the three months ended September 30, 2025, according to the company’s filing. Much of the comparison reflects differences in the timing of revenue between the periods: revenue in the year-earlier quarter included a $50 million milestone payment tied to Jemperli sales. AnaptysBio recorded no milestone payments in the current quarter, according to the filing. The decline in collaboration revenue alone therefore does not reflect a uniform trend in product royalties, one of whose main components grew. The distinction matters in reading quarterly revenue because the payment tied to a contractual milestone in the prior year raised the comparison base.
Jemperli royalty revenue rose to $29.565 million from $24.903 million a year earlier, while Zejula royalty revenue fell to $0.699 million from $1.360 million, according to company data. Royalties from the two products totaled $30.3 million in the quarter ended September 30, 2026. Jemperli royalties, however, were non-cash under the royalty monetization agreement, according to the 10-Q filing. GSK reports sales information to the company with a one-quarter lag, and differences between estimated and actual royalties are settled in the following quarter. The quarter’s figures are therefore tied to sales information available under the reporting and settlement process described by the company, with differences potentially reflected in the following period.
Cash, cash equivalents and investments totaled $153.0 million on September 30, 2026, compared with $164.1 million on June 30, according to the company’s filing. Continuing operations used $9.544 million in cash during the quarter, after providing $4.794 million in the corresponding period of 2025. The figures follow the spin-off of First Tracks Biotherapeutics, completed on April 20, 2026, leaving royalty management as AnaptysBio’s only operating segment. In light of its available resources, management said it expects to fund its current operating plan for at least 12 months from the date the financial statements are issued. That estimate represents the funding horizon announced by the company, while the cash and operating cash-flow figures show the movement of resources during the quarter.
The company changed its fiscal year-end on May 18, 2026, from December 31 to June 30, and began reporting quarterly results under the new fiscal year starting with the quarter ended September 30, according to its statement accompanying the SEC filing. In a separate legal development, AnaptysBio asked a Delaware court to enforce the rights reversion provision in its agreement with Tesaro and GSK and return the rights to dostarlimab to the company. Post-trial closing arguments were held on October 20, 2026, according to the filing. In the market, the company’s shares, listed under the ticker ANAB, closed at $47.77 on November 12, 2026, according to EL7 data. That is the closing price in the session before the news publication date; the available evidence does not include the daily trading range or the share-price move after the results were released.